EMA Reviews Public Communication Strategy
The EMA has unveiled a new survey to assess how its communication strategy to the general public is perceived and valued by its stakeholders.
The European Medicines Agency (EMA) has unveiled a new survey to assess how its communication strategy to the general public is perceived and valued by its stakeholders.
The survey addresses how the agency communicates to the general public, and focuses on information made public mainly through the EMA website, including press releases and news announcements. EMA plans to distribute the results of the analysis.
“This will provide valuable feedback to help us to better plan and carry out our communication activities,” noted Monika Benstetter, Head of Media and Public Relations at EMA. “This is the second communications survey, the first having taken place in 2015, and it is anticipated that this exercise will be repeated every two years.”
The survey will be open until May 31, 2017, and Benstetter estimates that it should take you no longer than 10 minutes to complete. To access it, click here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
